Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease
Movement Disorders · 2024
DOI: 10.1002/mds.29935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2024. Verfasst von Mary Kate LoPiccolo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Gaucher Disease, alpha-Synuclein, Skin, Parkinson Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Weston Brain Institute, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Patients with type 1 Gaucher disease (GD1) have a significantly increased risk of developing Parkinson's disease (PD).
Objective
The objective of this study was to evaluate skin α‐synuclein (αSyn) seeding activity as a biomarker for GD1‐related PD (GD1‐PD).
Methods
This single‐center study administered motor and cognitive examinations and questionnaires of nonmotor symptoms to adult patients with GD1. Optional skin biopsy was performed for skin αSyn seed amplification assay (αSyn SAA) using real‐time quaking‐induced conversion assay.
Results
Forty‐nine patients were enrolled, and 36 underwent skin biopsy. Two study participants had PD. Ten participants were αSyn SAA positive (27.8%), 7 (19.4%) were intermediate, and 19 (52.8%) were negative. Positive αSyn seeding activity was observed in the single GD1‐PD case who consented to biopsy. αSyn SAA positivity was associated with older age ( p = 0.043), although αSyn SAA positivity was more prevalent in patients with GD1 than historic controls.
Conclusions
Longitudinal follow‐up is required to determine whether skin αSyn seeding activity can be an early biomarker for GD1‐PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Departments of Pathology and Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Movement Disorders Division, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Institute of Neurology, Jiangxi Academy of Clinical Medical Sciences, Department of Neurology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Förderung
- Weston Brain Institute
- NINDS NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
LoPiccolo, M. K., Wang, Z., Eshed, G. M., Fierro, L., Stauffer, C., Wang, K., Zhang, J., Tatsuoka, C., Balwani, M., Zou, W. Q., & Alcalay, R. N. (2024). Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease. Movement Disorders. https://doi.org/10.1002/mds.29935
Vancouver
LoPiccolo MK, Wang Z, Eshed GM, Fierro L, Stauffer C, Wang K, et al. Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease. Movement Disorders. 2024. doi:10.1002/mds.29935
BibTeX
@article{LoPiccolo2024,
author = {LoPiccolo, Mary Kate and Wang, Zerui and Eshed, Gadi Maayan and Fierro, Luca and Stauffer, Chanan and Wang, Kelly and Zhang, Jing and Tatsuoka, Curtis and Balwani, Manisha and Zou, Wen-Quan and Alcalay, Roy N},
title = {Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease},
journal = {Movement Disorders},
year = {2024},
doi = {10.1002/mds.29935}
}
EUVIMED